Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, September 15, 2020
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
[ Tue, Sep 15th 2020
] - WOPRAI
Mon, September 14, 2020
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
[ Mon, Sep 14th 2020
] - WOPRAI
Paul Choi Upgraded (VIR) to Strong Buy and Increased Target to $54 on, Sep 14th, 2020
Paul Choi of Goldman Sachs, Upgraded "Vir Biotechnology, Inc." (VIR) to Strong Buy and Increased Target from $48 to $54 on, Sep 14th, 2020.
Paul has made no other calls on VIR in the last 4 months.
There are 2 other peers that have a rating on VIR. Out of the 2 peers that are also analyzing VIR, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $29 on, Friday, September 11th, 2020
This is the rating of the analyst that currently disagrees with Paul
- Alan Carr of "Needham" Initiated at Strong Buy and Held Target at $62 on, Thursday, August 20th, 2020
